Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial

被引：0
|
作者：
Jinsong Yang
Ai Huang
Kunyu Yang
Ke Jiang
机构：
[1] Union Hospital,Cancer Center
[2] Tongji Medical College,Department of Thoracic Surgery
[3] Huazhong University of Science and Technology,undefined
[4] Union Hospital,undefined
[5] Tongji Medical College,undefined
[6] Huazhong University of Science and Technology,undefined
来源：
BMC Cancer | / 23卷
关键词：
Esophageal carcinoma; Neoadjuvant; Chemoradiotherapy; Immunotherapy; Tislelizumab; Surgery; Pathologic complete response; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial
    Yang, Jinsong
    Huang, Ai
    Yang, Kunyu
    Jiang, Ke
    BMC CANCER, 2023, 23 (01)
  • [2] Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial
    Yang, J.
    Zhang, Z.
    Wu, B.
    Liu, C.
    Qin, Y.
    Wen, L.
    Wei, J.
    Xiao, G.
    Xing, S.
    Qu, Y.
    Huang, L.
    Wang, X.
    Wang, B.
    Zuo, Z.
    Can, F.
    Jiang, K.
    Yang, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E502 - E502
  • [3] Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial
    Yang, Jinsong
    Liu, Cui
    Zuo, Zhigang
    Cao, Fengjun
    Zhang, Zhanjie
    Wu, Bian
    Qin, You
    Wen, Lu
    Wei, Jielin
    Xiao, Guangqin
    Xing, Shijie
    Qu, Yue
    Huang, Lei
    Wang, Xiaolin
    Wang, Buhai
    Yang, Kunyu
    Jiang, Ke
    RADIOTHERAPY AND ONCOLOGY, 2025, 206
  • [4] Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
    Shiran, S.
    Huang, X.
    Wang, K.
    Wu, R.
    Wang, J.
    Zhang, Y.
    Qu, Y.
    Chen, X.
    Zhang, J.
    Luo, J.
    Yi, J.
    Zhou, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E791 - E791
  • [5] Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    Tang, Lin-Quan
    Luo, Meijuan
    Zhao, Chong
    Mo, Hao-Yuan
    Sun, Rui
    Luo, Dong-Hua
    Wang, Lin
    Guo, Shan-Shan
    Xie, Siyi
    Li, Su-Chen
    Liu, Sai-Lan
    Li, Xiao Yun
    Peng, Jing-Yun
    Qiu, Hui-Zhi
    Sun, Xue-Song
    Liu, LiTing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial
    Gui, Lin
    Liu, Shaoyan
    Wang, Xiaolei
    Zhang, Ye
    He, Xiaohui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial
    Wu, Wenjie
    Wang, Lin
    Zhang, Tong
    Zhang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Neoadjuvant tislelizumab plus chemotherapy among patients with advanced ovarian cancer: A prospective, single-arm, phase II study
    Zhou, Jinhua
    Liu, Wei
    Huang, Yazhen
    Ding, Hongmei
    Chen, Youguo
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S298 - S299
  • [9] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Ding, Chengzhi
    Guo, Yijun
    Zhou, Yaning
    He, Yi
    Chen, Chunji
    Zhang, Ming
    Guo, Xufeng
    BMC CANCER, 2023, 23 (01)
  • [10] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Chengzhi Ding
    Yijun Guo
    Yaning zhou
    Yi He
    Chunji Chen
    Ming Zhang
    Xufeng Guo
    BMC Cancer, 23
12345